The Technical Analyst
Scholar Rock Holding Corp [SRRK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Scholar Rock Holding Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.75% $13.94
America/New_York / 18 apr 2024 @ 15:32
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 085.49 mill |
| EPS: | -1.990 |
| P/E: | -7.01 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 77.87 mill |
| Avg Daily Volume: | 0.793 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.01 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.19x |
| Company: PE -7.01 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.480 (-96.55%) $-13.46 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 12.61 - 15.25 ( +/- 9.45%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Peng Katie | Buy | 35 767 | Stock Option (Right to Buy) |
| 2024-04-09 | Peng Katie | Buy | 26 825 | Common Stock |
| 2024-02-16 | Myles Edward H | Sell | 4 744 | Common Stock |
| 2024-02-16 | Qatanani Mo | Sell | 2 512 | Common Stock |
| 2024-02-16 | Parlavecchio Caryn | Sell | 3 751 | Common Stock |
| INSIDER POWER |
|---|
| 57.36 |
| Last 96 transactions |
| Buy: 9 442 259 | Sell: 2 434 527 |
Forecast:
16:00 - $13.94
Live Trading Signals (every 1 min)
Forecast
1: 15:41 - $13.95
Forecast 2: 16:00 - $13.94
Forecast 3: 16:00 - $13.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.94 (1.75% ) |
| Volume | 0.324 mill |
| Avg. Vol. | 0.793 mill |
| % of Avg. Vol | 40.85 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SRRK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $15.90 | N/A | Active |
|---|
SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-12 16:15:00 - Press Release
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk; the “company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 45,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purc.
2024-03-19 07:00:00 - Press Release
Scholar Rock Reports Full Year 2023 Financial Results And Highlights Business Progress
Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (sma), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended december 31, 2023. “in 2023, scholar rock made significant progress across our industry-leading antimyostatin pipeline, and we are.
2024-03-15 16:15:00 - Press Release
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk; the “company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards on march 11, 2024, covering an aggregate of 201,469 shares of its common stock to six newly hired employees, consisting of inducement s.
2024-02-28 08:00:00 - Press Release
Scholar Rock To Participate In Upcoming Investor Conferences
Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (sma), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in march: td cowen 44th annual health care conference: scholar rock is scheduled to participate in a fi.
2024-02-16 16:15:00 - Press Release
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk; “the company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (sma), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of its common stock to four newly hired employees, consisting of inducement stock options.
Latest News
2024-01-12 05:32:53 - Seeking Alpha
Scholar Rock: Solid Data And Good Prospects
Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024.
2024-01-02 13:57:42 - InvestorPlace
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction.
2023-11-07 14:18:02 - Seeking Alpha
Scholar Rock Holding Corporation (SRRK) Q3 2023 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Rushmie Nofsinger - Vice President, Investor Relations & Corporate Affairs Jay Backstrom - Chief Executive Officer Mo Qatanani - Head of Research. Ted Myles - Chief Operating Officer & Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Allison Bratzel - Piper Sandler Tessa Romero - JPMorgan Srikripa Devarakonda - Truist Securities Etzer Darout - BMO Capital Markets Andres Maldonado - H.C.Wainwright Ernesto Rodriguez-Dumont - Cowen Rushmie Nofsinger Good morning.
2023-11-06 11:17:42 - Zacks Investment Research
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-10-31 10:33:01 - Zacks Investment Research
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2023-10-25 17:44:30 - Seeking Alpha
Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look
The Scholar Rock Holding Corporation phase 3 SAPPHIRE study for apitegromab for the treatment of type 2 and type 2 SMA patients has completed enrollment and is expected to report results in Q4 2024. Data from the TOPAZ study showed consistent gains in motor function scores for SMA patients treated with apitegromab. It is expected that the global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032.
2023-10-24 13:32:35 - Zacks Investment Research
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-10-13 14:16:13 - Zacks Investment Research
Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
2023-10-12 16:17:24 - The Motley Fool
Why Scholar Rock Holding Stock Soared Today
Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with a phase 2 proof-of concept trial in 2024. The biopharma company will work toward an investigational new drug (IND) application submission in 2025.
2023-09-25 09:01:44 - Zacks Investment Research
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).